CompletedEUCTR 2009-018161-12
A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adol...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesADHD
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium · Germany and 5 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 510
- Sponsor
- Shire Development Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United Kingdom, Belgium, Germany, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2009-018161-12
- Official title
Show the full official title
A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adol...
Get this study by email
Recruitment & locations
CompletedBelgium · Germany · Italy
4 more locations
- Netherlands
- Spain
- Sweden
- United Kingdom
Registry details
Historical country statuses
- Belgium — Completed
- Germany — Completed
- Spain — Completed
- United Kingdom — Completed
- Italy — Completed
- Netherlands — Completed
- Sweden — Completed
Questions about this study
Who is behind this study?
The study sponsor is Shire Development Inc.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...